Clinical Trials Logo

Clinical Trial Summary

This pilot clinical trial studies gallium Ga 68-edotreotide (68Ga-DOTATOC) positron emission tomography (PET)/computed tomography (CT) in finding brain tumors in younger patients. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT imaging, may help find and diagnose brain tumors.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine if 68Ga-DOTATOC (gallium Ga 68-edotreotide) PET when combined with magnetic resonance imaging (MRI) will differentiate embryonal tumors such as medulloblastoma and supratentorial primitive neuroectodermal tumor (PNET) from the low and high grade gliomas.

II. To determine if 68Ga-DOTATOC PET will aid in the identification of residual tumor post operatively in those patients who were 68Ga-DOTATOC PET positive prior to surgery.

OUTLINE:

Patients undergo gallium Ga 68-edotreotide PET/CT at baseline and 1-30 days after surgery. ;


Study Design


Related Conditions & MeSH terms

  • Acoustic Schwannoma
  • Adult Anaplastic Astrocytoma
  • Adult Anaplastic Ependymoma
  • Adult Anaplastic Meningioma
  • Adult Anaplastic Oligodendroglioma
  • Adult Brain Stem Glioma
  • Adult Choroid Plexus Tumor
  • Adult Craniopharyngioma
  • Adult Diffuse Astrocytoma
  • Adult Ependymoblastoma
  • Adult Ependymoma
  • Adult Giant Cell Glioblastoma
  • Adult Glioblastoma
  • Adult Gliosarcoma
  • Adult Grade I Meningioma
  • Adult Grade II Meningioma
  • Adult Medulloblastoma
  • Adult Meningeal Hemangiopericytoma
  • Adult Mixed Glioma
  • Adult Myxopapillary Ependymoma
  • Adult Oligodendroglioma
  • Adult Papillary Meningioma
  • Adult Pilocytic Astrocytoma
  • Adult Pineal Gland Astrocytoma
  • Adult Pineoblastoma
  • Adult Pineocytoma
  • Adult Subependymal Giant Cell Astrocytoma
  • Adult Subependymoma
  • Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)
  • Astrocytoma
  • Brain Neoplasms
  • Childhood Choroid Plexus Tumor
  • Childhood Craniopharyngioma
  • Childhood Ependymoblastoma
  • Childhood Grade I Meningioma
  • Childhood Grade II Meningioma
  • Childhood Grade III Meningioma
  • Childhood High-grade Cerebellar Astrocytoma
  • Childhood High-grade Cerebral Astrocytoma
  • Childhood Infratentorial Ependymoma
  • Childhood Low-grade Cerebellar Astrocytoma
  • Childhood Low-grade Cerebral Astrocytoma
  • Childhood Medulloepithelioma
  • Childhood Supratentorial Ependymoma
  • Choroid Plexus Neoplasms
  • Craniopharyngioma
  • Ependymoma
  • Glioblastoma
  • Glioma
  • Gliosarcoma
  • Hemangiopericytoma
  • Medulloblastoma
  • Meningeal Melanocytoma
  • Meningioma
  • Neoplasms
  • Neoplasms, Neuroepithelial
  • Neurilemmoma
  • Neuroectodermal Tumors
  • Neuroectodermal Tumors, Primitive
  • Neuroma, Acoustic
  • Newly Diagnosed Childhood Ependymoma
  • Oligodendroglioma
  • Optic Nerve Glioma
  • Pinealoma
  • Recurrent Adult Brain Tumor
  • Recurrent Childhood Anaplastic Astrocytoma
  • Recurrent Childhood Anaplastic Oligoastrocytoma
  • Recurrent Childhood Anaplastic Oligodendroglioma
  • Recurrent Childhood Brain Stem Glioma
  • Recurrent Childhood Cerebellar Astrocytoma
  • Recurrent Childhood Cerebral Astrocytoma
  • Recurrent Childhood Diffuse Astrocytoma
  • Recurrent Childhood Ependymoma
  • Recurrent Childhood Fibrillary Astrocytoma
  • Recurrent Childhood Gemistocytic Astrocytoma
  • Recurrent Childhood Giant Cell Glioblastoma
  • Recurrent Childhood Glioblastoma
  • Recurrent Childhood Gliomatosis Cerebri
  • Recurrent Childhood Gliosarcoma
  • Recurrent Childhood Medulloblastoma
  • Recurrent Childhood Oligoastrocytoma
  • Recurrent Childhood Oligodendroglioma
  • Recurrent Childhood Pilocytic Astrocytoma
  • Recurrent Childhood Pilomyxoid Astrocytoma
  • Recurrent Childhood Pineoblastoma
  • Recurrent Childhood Pleomorphic Xanthoastrocytoma
  • Recurrent Childhood Protoplasmic Astrocytoma
  • Recurrent Childhood Subependymal Giant Cell Astrocytoma
  • Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
  • Recurrent Childhood Visual Pathway and Hypothalamic Glioma
  • Recurrent Childhood Visual Pathway Glioma
  • Untreated Childhood Anaplastic Astrocytoma
  • Untreated Childhood Anaplastic Oligodendroglioma
  • Untreated Childhood Brain Stem Glioma
  • Untreated Childhood Cerebellar Astrocytoma
  • Untreated Childhood Cerebral Astrocytoma
  • Untreated Childhood Diffuse Astrocytoma
  • Untreated Childhood Fibrillary Astrocytoma
  • Untreated Childhood Gemistocytic Astrocytoma
  • Untreated Childhood Giant Cell Glioblastoma
  • Untreated Childhood Glioblastoma
  • Untreated Childhood Gliomatosis Cerebri
  • Untreated Childhood Gliosarcoma
  • Untreated Childhood Medulloblastoma
  • Untreated Childhood Oligoastrocytoma
  • Untreated Childhood Oligodendroglioma
  • Untreated Childhood Pilocytic Astrocytoma
  • Untreated Childhood Pilomyxoid Astrocytoma
  • Untreated Childhood Pineoblastoma
  • Untreated Childhood Pleomorphic Xanthoastrocytoma
  • Untreated Childhood Protoplasmic Astrocytoma
  • Untreated Childhood Subependymal Giant Cell Astrocytoma
  • Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
  • Untreated Childhood Visual Pathway and Hypothalamic Glioma
  • Untreated Childhood Visual Pathway Glioma

NCT number NCT02194452
Study type Interventional
Source University of Iowa
Contact
Status Withdrawn
Phase N/A
Start date September 2013
Completion date March 2017

See also
  Status Clinical Trial Phase
Terminated NCT02530502 - Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Phase 1
Completed NCT00238303 - Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Phase 2
Completed NCT02227901 - Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1
Completed NCT00049387 - Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Phase 1
Completed NCT02015819 - Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Phase 1
Active, not recruiting NCT02179086 - Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Phase 2
Recruiting NCT04573140 - A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) Phase 1
Active, not recruiting NCT00823797 - Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Phase 2
Completed NCT00045565 - Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Completed NCT01977677 - Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Phase 1/Phase 2
Completed NCT01648348 - Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00004262 - Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme Phase 1
Terminated NCT01996527 - 3T MRI Biomarkers of Glioma Treatment Response Early Phase 1
Terminated NCT01575275 - Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme Phase 2
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT01103375 - Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma Phase 1
Completed NCT01119599 - RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Completed NCT00459381 - Pazopanib in Treating Patients With Recurrent Glioblastoma Phase 2
Completed NCT00316849 - Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1
Completed NCT00016328 - CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme Phase 2